{"id":242372,"date":"2012-12-01T01:41:21","date_gmt":"2012-12-01T01:41:21","guid":{"rendered":"http:\/\/www.eugenesis.com\/heptares-chief-scientific-officer-and-founder-fiona-marshall-receives-prestigious-uk-women-of-outstanding-achievement\/"},"modified":"2012-12-01T01:41:21","modified_gmt":"2012-12-01T01:41:21","slug":"heptares-chief-scientific-officer-and-founder-fiona-marshall-receives-prestigious-uk-women-of-outstanding-achievement","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biochemistry\/heptares-chief-scientific-officer-and-founder-fiona-marshall-receives-prestigious-uk-women-of-outstanding-achievement.php","title":{"rendered":"Heptares Chief Scientific Officer and Founder Fiona Marshall Receives Prestigious UK &#8220;Women of Outstanding Achievement &#8230;"},"content":{"rendered":"<p><p>    WELWYN GARDEN CITY, England and BOSTON, November 30, 2012    \/PRNewswire\/ --  <\/p>\n<p>    Heptares Therapeutics, the leading GPCR drug discovery company,    is delighted to announce that its Chief Scientific Officer and    founder, Fiona Marshall, has received a 2012 Women of    Outstanding Achievement Award from WISE, a UK national campaign    to promote female talent in science, engineering, technology    and the built environment. Dr Marshall received the award in    the Innovation and Entrepreneurship category in recognition of    her academic and industry achievements as well as her positive    contributions in attracting women to the life sciences area.  <\/p>\n<p>    Dr Marshall received her award from Her Royal Highness, The    Princess Royal at the prestigious WISE Awards held yesterday at    The Institution of Technology and Engineering in London, UK.  <\/p>\n<p>    \"I'm very grateful to receive this award. I have seen Heptares    grow from just two of us in a portacabin to a world-leading    biotech company with more than 60 scientists, including women    from around the world, working in chemistry, crystallography,    biochemistry and pharmacology. It has been wonderful to work    with so many talented young scientists.\" commented Dr Marshall.    \"This team is central to Heptares' leadership in the GPCR    field, solving the structures of clinically important GPCRs and    leveraging this structural insight to discover and design    exciting new drug candidates. Heptares today has a substantial    pipeline of unique agents in development for treating serious    diseases such as Alzheimer's disease, schizophrenia, chronic    insomnia, addiction disorders, migraine and diabetes, as well    as partnerships with multiple leading pharmaceutical    companies.\"  <\/p>\n<p>    Malcolm Weir, Heptares' CEO, added: \"Fiona is an exceptional    scientist and on behalf of all of us at Heptares, we    congratulate her on receiving this award in recognition of her    work; it is very well deserved.\"  <\/p>\n<p>    Biography  <\/p>\n<p>    Dr Marshall received a BSc in biochemistry from Bath University    and a PhD in neuroscience from Cambridge University. She has    more than 20 years' experience in drug discovery with    particular expertise on GPCRs, is inventor of seven patents and    author of over 60 peer-reviewed scientific papers in the area    of GPCRs. Her work has contributed to the development of drugs    for asthma, schizophrenia, heart disease and Parkinson's    disease.  <\/p>\n<p>    Dr Marshall set up Heptares Therapeutics, one of the UK's    leading biotechnology companies, with Malcolm Weir in 2006. She    now leads a team of 60 scientists at Heptares, which is    pioneering a structure-based drug design approach to GPCRs and    building a broad pipeline of novel medicines to transform the    treatment of serious diseases. Heptares has established drug    R&D collaborations with Shire, Takeda, AstraZeneca and    Medimmune.  <\/p>\n<p>    Before Heptares, Dr Marshall spent 12 years at    GlaxoWellcome\/GlaxoSmithKline where she held a number of senior    positions including Head of the Department of Molecular    Pharmacology and Head of GPCR research. She was Director of    Discovery Pharmacology, Europe for Millennium Pharmaceuticals    and then spent several years as an independent consultant to a    variety of venture capital and biotech companies. She was chair    of the BBSRC biochemistry and cell biology committee for three    years and is currently Chair of the CRUK Drug Discovery    Committee and Vice-chair of the Wellcome Trust Seeding Drug    Discovery Committee.  <\/p>\n<p>    A short video clip can be seen by clicking     here.  <\/p>\n<\/p>\n<p>See the article here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/heptares-chief-scientific-officer-founder-104700075.html;_ylt=A2KJjakyYLlQ1Q8AjwH_wgt.\" title=\"Heptares Chief Scientific Officer and Founder Fiona Marshall Receives Prestigious UK &quot;Women of Outstanding Achievement ...\">Heptares Chief Scientific Officer and Founder Fiona Marshall Receives Prestigious UK &quot;Women of Outstanding Achievement ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> WELWYN GARDEN CITY, England and BOSTON, November 30, 2012 \/PRNewswire\/ -- Heptares Therapeutics, the leading GPCR drug discovery company, is delighted to announce that its Chief Scientific Officer and founder, Fiona Marshall, has received a 2012 Women of Outstanding Achievement Award from WISE, a UK national campaign to promote female talent in science, engineering, technology and the built environment. Dr Marshall received the award in the Innovation and Entrepreneurship category in recognition of her academic and industry achievements as well as her positive contributions in attracting women to the life sciences area <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biochemistry\/heptares-chief-scientific-officer-and-founder-fiona-marshall-receives-prestigious-uk-women-of-outstanding-achievement.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577469],"tags":[],"class_list":["post-242372","post","type-post","status-publish","format-standard","hentry","category-biochemistry"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/242372"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=242372"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/242372\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=242372"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=242372"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=242372"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}